DDInter1702 DDInter119
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma.
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.
Sorafenib {u} (Compound) resembles {v} (Compound) Vismodegib
Sorafenib {u} (Compound) treats {v} (Disease) liver cancer
Sorafenib {u} (Compound) binds {v} (Gene) BRAF
Sorafenib {u} (Compound) upregulates {v} (Gene) TSC22D3
Sorafenib {u} (Compound) downregulates {v} (Gene) MCM3
Sorafenib {u} (Compound) causes {v} (Side Effect) Hepatobiliary disease
Sorafenib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trimipramine
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tacrine
Sorafenib {u} may lead to a major life threatening interaction when taken with {v} Ibutilide
Sorafenib (Compound) resembles Vismodegib (Compound)
Sorafenib (Compound) treats liver cancer (Disease)
Sorafenib (Compound) binds BRAF (Gene)
Sorafenib (Compound) upregulates TSC22D3 (Gene)
Sorafenib (Compound) downregulates MCM3 (Gene)
Sorafenib (Compound) causes Hepatobiliary disease (Side Effect)
Sorafenib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Tacrine
Sorafenib may lead to a major life threatening interaction when taken with Ibutilide